At a Glance
- Market value: USD 1,140 million in 2025
- Forecast value: USD 1,955 million by 2031
- Forecast CAGR: 9.41% (2026-2031)
- Test volume: 815 million equivalents in 2025, projected 1,280 million in 2031
- Dominant segment: Infectious Disease Rapid Tests
- Fastest‑growing segment: Molecular amplification technologies
- Total players: 85
What Is Changing in the India POCT Market?
The India Point‑of‑Care Testing (POCT) market is shifting from stand‑alone rapid kits toward connected, consumable‑led diagnostic platforms, a transition driven by expanding primary‑care infrastructure and digital health integration. India POCT Market revenue is projected to climb from USD 1,140 million in 2025 to USD 1,955 million by 2031, reflecting a 9.41% forecast CAGR that outpaces the historical 7.34% CAGR recorded from 2020‑2025.
Why Is Decentralized Primary‑Care Diagnostics Important for the India POCT Market?
Impact on Market Demand
Demand is anchored in high‑frequency screening and monitoring. The National NCD Portal enrolled 74.97 crore beneficiaries by December 2025, creating a broad funnel for near‑patient glucose, HbA1c, lipid and cardiovascular testing. Public facilities now offer 14 tests at sub‑centres and 63 tests at primary health centres, expanding tender opportunities and low‑cost consumable pull‑through.
Impact on Competition
Domestic manufacturers can capture value through localized reagents, cartridge production and instrument‑rental models, while multinational suppliers retain advantages in assay breadth, quality systems and hospital connectivity. The market remains moderately concentrated, with Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation and Becton, Dickinson and Company accounting for roughly 70% of the share.
Impact on Market Growth
Test volume is expected to rise from 815 million equivalents in 2025 to 1,280 million by 2031, a 7.82% volume CAGR. The blended value per test improves as molecular, immunofluorescence and connected‑analyzer formats gain share, supporting the overall 9.41% value CAGR.
What Does the Ken Research Report Reveal About Market Opportunities?
Largest Product Segment
Glucose monitoring products remain the largest recurring revenue pool, driven by frequent strip and lancet purchases across household and clinical use.
Fastest‑Growing Segment
Molecular amplification is the fastest‑growing technology, offering near‑laboratory sensitivity in a portable format. Growth depends on affordable cartridges, battery‑backed operation and seamless connectivity.
Regional Opportunity
South India is the dominant region, while major hospital and diagnostic clusters in Maharashtra, Karnataka, Tamil Nadu, Telangana, Delhi NCR and Gujarat concentrate commercial demand. Rural expansion is supported by 1,81,873 operational Ayushman Arogya Mandirs (AAMs) and 494.71 crore cumulative footfall in 2025.
Public‑Sector Tender Opportunity
Public procurement expands the addressable base, with 41.93 crore teleconsultations through AAMs in 2025 enabling referral‑based testing and same‑visit treatment decisions.
What Does the Market Shift Mean for Businesses?
Interpretation: The report suggests that firms that invest in localized reagent manufacturing and analyzer‑as‑a‑service models can improve gross margins and tender competitiveness, while those that ignore connectivity may miss recurring software‑service revenue streams.
Aftermarket and Recurring Revenue Opportunities
Connected POCT and managed testing networks allow vendors to monetize software dashboards, operator credentialing and fleet management, converting one‑time hardware sales into multi‑year service contracts.
Market Adoption and Execution Challenges
Key execution risks include price compression from public tendering, operator training gaps, and lot‑to‑lot quality‑control variability. ISO 15189:2022 integration of POCT governance raises the evidence burden for Class C and D products, increasing launch costs for high‑value molecular and cardiac assays.
What Should India POCT Market Participants Watch Next?
- Expansion of localized reagent and cartridge production under the medical‑device PLI program.
- Adoption of connected analyzer platforms linked to the ABDM dashboard and ABHA identifiers.
- Regulatory evolution around Class C/D IVDs and ISO 15189:2022 compliance.
- Price dynamics in public‑sector tenders for high‑volume consumables.
- Operator training and quality‑control frameworks across AAM networks.
How Can Businesses Apply These Market Findings?
Interpretation: Businesses operating in the India Point‑of‑Care Testing (POCT) ecosystem can translate the market’s structural shifts into actionable strategies by aligning product portfolios with the evolving demand for connected, consumable‑led platforms. The forecasted 9.41% CAGR from 2025 to 2031, coupled with a projected test volume rise to 1,280 million equivalents, signals that recurring consumable economics will remain the primary revenue driver. Firms should therefore prioritize the development of low‑cost, high‑frequency test kits—particularly glucose monitoring strips and rapid infectious‑disease assays—while simultaneously investing in modular cartridge production that can be localized to meet the 1,81,873 operational Ayushman Arogya Mandirs (AAMs) and the broader rural network. By establishing regional manufacturing hubs, companies can reduce supply chain lead times, lower import duties, and position themselves favorably in public‑sector tenders, where price compression is a key risk factor.
Interpretation: Another critical lever is the shift toward connected analyzers and digital health integration. The market’s move from stand‑alone rapid kits to platforms that combine consumables with meters, readers, and compact analyzers creates a recurring revenue stream beyond the initial hardware sale. Vendors that embed software dashboards, operator credentialing modules, and fleet‑management tools can monetize these services through subscription or usage‑based models, converting a one‑time transaction into multi‑year contracts. This approach not only improves gross margins but also enhances customer lock‑in, especially within the public‑sector ecosystem where the 41.93 crore teleconsultations through AAMs in 2025 enable referral‑based testing and same‑visit treatment decisions. By aligning software offerings with the ABDM dashboard and ABHA identifiers, companies can tap into the growing digital record linkage that supports seamless data flow between community sites, clinicians, and confirmatory laboratories.
Interpretation: Strategic partnerships with local reagent manufacturers also present a pathway to capture value. The forecast indicates that domestic players can benefit from localized reagent production, instrument‑rental models, and public tenders, while multinational suppliers retain advantages in assay breadth and quality systems. A hybrid model—where a multinational partner supplies high‑value molecular or cardiac assays and a domestic partner handles low‑cost consumables and distribution—can balance cost, quality, and market reach. This collaboration can mitigate execution risks such as operator training gaps and lot‑to‑lot quality control variability, which are amplified in decentralized care settings. By sharing expertise, firms can accelerate time‑to‑market for new assays and ensure compliance with ISO 15189:2022, thereby reducing launch costs for high‑value products.
Interpretation: Finally, businesses must monitor regulatory evolution and public‑sector tender dynamics. The medical‑device PLI program’s push for localized reagent and cartridge production, coupled with the tightening of Class C/D IVD regulations, will reshape competitive dynamics. Companies that proactively engage with regulatory bodies to streamline approval pathways and that develop robust quality‑control frameworks across AAM networks will be better positioned to secure tender contracts and maintain high service standards. In parallel, staying attuned to price trends in public‑sector tenders for high‑volume consumables will enable firms to adjust pricing strategies and maintain profitability in a market where price compression is a persistent challenge.
Conclusion: India POCT Market Outlook
The India POCT market is poised for robust growth, with a 9.41% CAGR projected through 2031, driven by decentralized testing, expanding primary‑care infrastructure and a shift toward connected, consumable‑centric platforms. Companies that localize consumables, embrace connectivity and navigate regulatory complexities will be best positioned to capture the expanding value pool.
